Literature DB >> 18567282

Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report.

Jennifer B Merriman1, Juan M Gonzalez, Jack Rychik, Serdar H Ural.   

Abstract

BACKGROUND: Neonatal survival and prognosis are closely linked with development of hydrops in cases of sustained fetal tachycardia. Several antiarrhythmic medications are available for conversion to sinus rhythm. CASE: An 18-year-old woman had an audible fetal arrhythmia at 25 weeks' gestation. Fetal echocardiography revealed supraventricular tachycardia with worsening cardiac function at 28 weeks. Digoxin therapy was initiated and sotalol was later added for new-onset hydrops. The medications were then adjusted, and the fetus' heart rate converted to sinus rhythm with resolution of the hydrops. The patient was then managed as an outpatient with antenatal testing, serial laboratory studies and electrocardiograms until 39 weeks.
CONCLUSION: Digoxin and sotalol therapy can be successful in blocking likely nodal reentry in sustained fetal supraventricular tachycardia, thus allowing resolution of hydrops with a favorable outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567282

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

Review 1.  Prenatal pharmacotherapy for fetal anomalies: a 2011 update.

Authors:  Lisa Hui; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2011-06-03       Impact factor: 3.050

2.  Drug resistant fetal arrhythmia in obstetric cholestasis.

Authors:  Nahide Altug; Ayse Kirbas; Korkut Daglar; Ebru Biberoglu; Dilek Uygur; Nuri Danisman
Journal:  Case Rep Obstet Gynecol       Date:  2015-03-03

3.  Brazilian Fetal Cardiology Guidelines - 2019.

Authors:  Simone R F Fontes Pedra; Paulo Zielinsky; Cristiane Nogueira Binotto; Cristiane Nunes Martins; Eduardo Sérgio Valério Borges da Fonseca; Isabel Cristina Britto Guimarães; Izabele Vian da Silveira Corrêa; Karla Luiza Matos Pedrosa; Lilian Maria Lopes; Luiz Henrique Soares Nicoloso; Marcia Ferreira Alves Barberato; Marina Maccagnano Zamith
Journal:  Arq Bras Cardiol       Date:  2019-06-06       Impact factor: 2.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.